BR9916043A - Compound, use of the same and its pharmaceutically acceptable salts, and pharmaceutical composition for the treatment of viral herpes infections in patients - Google Patents

Compound, use of the same and its pharmaceutically acceptable salts, and pharmaceutical composition for the treatment of viral herpes infections in patients

Info

Publication number
BR9916043A
BR9916043A BR9916043-9A BR9916043A BR9916043A BR 9916043 A BR9916043 A BR 9916043A BR 9916043 A BR9916043 A BR 9916043A BR 9916043 A BR9916043 A BR 9916043A
Authority
BR
Brazil
Prior art keywords
patients
compound
treatment
pharmaceutical composition
same
Prior art date
Application number
BR9916043-9A
Other languages
Portuguese (pt)
Inventor
Jonathan David Bloom
Kevin Joseph Curran
Martin Josephdigrandi
Russell George Dushin
Thomas Richard Jones
Stanleyalbert Lang
Adma Antonia Ross
Eugene Anthony Terefenko
Rian Mark O'hara
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of BR9916043A publication Critical patent/BR9916043A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C335/20—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C335/22—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)

Abstract

"COMPOSTO, USO DO MESMO E DE SEUS SAISFARMACêUTICAMENTE ACEITáVEIS E, COMPOSIçãOFARMACêUTICA PARA TRATAMENTO DE INFECçõES DEHERPES VIRAL EM PACIENTES". A presente invenção refere-sea compostos poliaromáticos tendo atividade antiviral útil contravírus da família do herpes, a uma composição que os contém, e aum processo de usá-los para o tratamento de infecções de vírusde herpes."COMPOUND, USE OF THE SAME AND ITS ACCEPTABLE SAISPharmacy AND, PHARMACEUTICAL COMPOSITION FOR TREATING DEHERPES VIRAL INFECTIONS IN PATIENTS". The present invention relates to polyaromatic compounds having useful antiviral activity against the herpes family, to a composition containing them, and to a process of using them for the treatment of herpes virus infections.

BR9916043-9A 1998-12-09 1999-12-06 Compound, use of the same and its pharmaceutically acceptable salts, and pharmaceutical composition for the treatment of viral herpes infections in patients BR9916043A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20816498A 1998-12-09 1998-12-09
PCT/US1999/028916 WO2000034261A2 (en) 1998-12-09 1999-12-06 Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing a substituted phenylenediamine group

Publications (1)

Publication Number Publication Date
BR9916043A true BR9916043A (en) 2001-12-04

Family

ID=22773466

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916043-9A BR9916043A (en) 1998-12-09 1999-12-06 Compound, use of the same and its pharmaceutically acceptable salts, and pharmaceutical composition for the treatment of viral herpes infections in patients

Country Status (14)

Country Link
EP (1) EP1144399A3 (en)
JP (1) JP2002533301A (en)
KR (1) KR20010086091A (en)
CN (1) CN1367785A (en)
AU (1) AU2353900A (en)
BR (1) BR9916043A (en)
CA (1) CA2351690A1 (en)
CZ (1) CZ20012063A3 (en)
EA (1) EA200100639A1 (en)
HU (1) HUP0203405A2 (en)
IL (1) IL143263A0 (en)
NO (1) NO20012835L (en)
WO (1) WO2000034261A2 (en)
ZA (1) ZA200104322B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
ATE311366T1 (en) 2000-02-29 2005-12-15 Millennium Pharm Inc BENZAMIDE AND SIMILAR FACTOR XA INHIBITORS
EA010017B1 (en) * 2003-07-10 2008-06-30 Ачиллион Фармасьютикалз, Инк. Substituted arylthiourea derivatives useful as inhibitors of viral replication
DE102004015007A1 (en) 2004-03-26 2005-10-13 Bayer Healthcare Ag Substituted imidazoles
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
DE102005008183A1 (en) 2005-02-23 2006-08-31 Bayer Healthcare Ag New heterocyclylamide-substituted imidazole compounds useful to treat or prevent viral infections
ES2382055T3 (en) 2006-11-02 2012-06-04 Millennium Pharmaceuticals, Inc. Methods for synthesizing pharmaceutical salts of a factor Xa inhibitor
EP2914592B1 (en) * 2012-11-03 2017-10-11 Boehringer Ingelheim International GmbH Inhibitors of cytomegalovirus
US9284310B2 (en) 2012-11-03 2016-03-15 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
CN112807294B (en) * 2019-11-18 2023-09-05 武汉大学 Application of acyl thiourea compound in preparation of medicines for treating or preventing herpes simplex virus type I infection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2243370T3 (en) * 1997-04-10 2005-12-01 PHARMACIA & UPJOHN COMPANY LLC POLYAROMATIC COMPOSITIONS FOR THE TREATMENT OF INFECTIONS BY VIRUS HERPES.

Also Published As

Publication number Publication date
CA2351690A1 (en) 2000-06-15
KR20010086091A (en) 2001-09-07
WO2000034261A3 (en) 2002-01-31
NO20012835D0 (en) 2001-06-08
CN1367785A (en) 2002-09-04
ZA200104322B (en) 2002-10-25
EP1144399A2 (en) 2001-10-17
AU2353900A (en) 2000-06-26
EA200100639A1 (en) 2002-06-27
EP1144399A3 (en) 2002-09-11
CZ20012063A3 (en) 2001-10-17
IL143263A0 (en) 2002-04-21
JP2002533301A (en) 2002-10-08
WO2000034261A2 (en) 2000-06-15
NO20012835L (en) 2001-07-19
HUP0203405A2 (en) 2003-02-28

Similar Documents

Publication Publication Date Title
BR9810745A (en) Benzimidazole derivatives
BR0008840A (en) Camptothecin derivatives having antitumor activity
EA200100541A1 (en) PHARMACEUTICAL COMPOSITION WITH MODIFIED SURVIVAL OF THE SENSITIZER TO INSULIN AND OTHER ANTI-DIABETIC AGENTS
MY117892A (en) Therapeutic compounds
DK0973735T3 (en) Polyaromatic antiviral preparations
YU7296A (en) Novel pharmaceutical combination containing antivirus substance and one anti-inflamatory glucocorticoid
MD1224B2 (en) Application of nucleoside analogues with 1,3-oxathiolan for treatment of hepatitis B
PT741577E (en) USING THE ALPHA INTERFERENCE SUBTYPE 8 IN THE PREPARATION OF MEDICINES FOR TREATING FIGURE VIRAL INFECTIONS
BR9913945A (en) Pharmaceutical composition for the treatment of acute disorders through sublingual administration, and, process for the treatment of acute disorders
PT100199A (en) Antiviral Combination of Nucleosides and Process for Preparation
BR9813373A (en) Compound, process for preparing it, pharmaceutical composition, process for preparing it, use of a compound, and, processes for effecting immunosuppression and for treating or reducing the risk of reversibly obstructive airway disease in a patient
BR9814375A (en) Inhibition of raf kinase using symmetrical and asymmetric substituted diphenyl urea
BR9711098A (en) New hysterocyclic compounds, process for their preparation and pharmaceutical compositions containing and their use in the treatment of diabetes and related diseases.
BR9909474A (en) Forms ii, crystalline ev of 5,6-dichloro-2- (isopropylamino) -1-beta-1-ribofuranosyl -1h-benzimidazole, 5,6-dichloro-2- (isopropylamino) -1-beta- ethanol solvate l-ribofuranosyl -1h-benzimidazole, composition, compound, use of 5,6-dichloro-2- (isopropylamino) -1-beta-l-ribofuranosyl -1h-benzimidazole, and processes for the treatment of a viral infection in a and for the production of 5,6-dichloro-2- (isopropylamino) -1-beta-1-ribofuranosyl -1h-benzimidazole
BR9916043A (en) Compound, use of the same and its pharmaceutically acceptable salts, and pharmaceutical composition for the treatment of viral herpes infections in patients
BR9910071A (en) Pharmaceutical composition, processes for increasing and maintaining the homogeneity of a pharmaceutical composition and for treating, reversing, reducing or inhibiting retroviral infections, use of abacavir, lamivudine, zidovudine or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable gliding agent , article of manufacture, and, process for the preparation of a pharmaceutical composition
BR9809126A (en) Compound, process for treating viral infection in a human host, use of a compound, and pharmaceutical formulation
NZ324380A (en) Therapeutic benzimidazole compounds and their use in treatment of virus infections
DK178188A (en) ANTIVIRUS AGENT
BR9706938A (en) Compound use of the same pharmaceutical formulation and processes to produce the compound and for the treatment or prevention of symptoms or effects of a viral infection in an infected mammal including a human
BR9712614A (en) Pharmaceutical composition, processes for increasing and maintaining the homogeneity of a pharmaceutical & eutectic composition, for treating, reversing, reducing or inhibiting retroviral infections and for preparing a pharmaceutical composition, use of lamivudine or a pharmaceutically acceptable derivative thereof, of zidovudine, or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable glidant; and, an article of manufacture.
BR9407862A (en) Flavin compound flavin derived from flavin or a mixture comprising two or more of these pharmaceutical composition and process for treatment by prophylaxis or therapy of disease caused by viral infection
BR9910185A (en) Use of a compound, and, process for the treatment of a patient suffering from, or at risk for, a mycobacterial disease
ES2128353T3 (en) TOPIC COMPOSITION CONTAINING PENCICLOVIR.
BR9808305A (en) Crystalline hydrated form, process for the preparation of hydrated crystalline form, pharmaceutical composition, process for treating a mammal, and process for treating or preventing pain.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]